Introduction
============

Fludarabine-containing regimens are typically used in the frontline treatment of chronic lymphocytic leukaemia (CLL), but relapse is common and response rate with re-treatment is generally inferior to response as first-line treatment.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ There is thus a need to develop new and non-cross-resistant drug combinations for relapsing patients. Inhibition of histone deacetylases (HDACs) using pharmacological agents, such as depsipeptide, suberoylanilide hydroxamic acid and valproic acid (VPA) is a novel strategy to treat such patients. *In vitro* results with HDAC inhibitors (HDIs) using depsipeptide, LBH589 and MS-275 were promising, implicating a number of different mechanisms associated with the inhibition of HDACs in CLL cells.^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8]^ However, in the clinic, HDI monotherapy trials in CLL have been disappointing. A phase I trial with depsipeptide observed no responses, despite obvious increases in the level of acetylated histones and p21 *in vivo.*^[@bib9]^ A phase II trial using MGCD0103 in previously treated CLL patients also produced no responses, despite some patients receiving concomitant rituximab.^[@bib10]^ Although both depsipeptide and MGCD0103 were tolerable, haematological grade 4 toxicity was observed with both drugs.^[@bib9],\ [@bib10]^

As HDIs as monotherapy are not effective in CLL, we rationalized that VPA might be more useful if combined with chemotherapy. VPA is a first-generation antiepileptic that has class I HDAC inhibition activity with half-maximal inhibitory concentration values for HDAC1--3 of⩽1 m[M]{.smallcaps}.^[@bib11],\ [@bib12],\ [@bib13]^ Treatment of CLL cells *in vitro* with VPA has been shown to induce apoptosis, as judged by caspase activation and Annexin V staining, whereas VPA inhibited proliferation of CLL cells induced by oligonucleotide and interleukin-2 co-stimulation.^[@bib14],\ [@bib15],\ [@bib16]^ Single-agent VPA was sufficient to induce alterations in the gene expression level of a large number of genes and to change the Bcl-2/Bax ratio at the protein level.^[@bib16],\ [@bib17]^ Further, VPA enhanced the effects of various chemotherapeutic agents on CLL cells, including fludarabine, bortezomib, flavopiridol, thalidomide and lenalidomide.^[@bib14],\ [@bib16]^ Oral formulation, with high bioavailability, makes VPA easy to administer to patients, and doses of 20--25 mg/kg per day are commonly used in adolescents and adults.^[@bib18],\ [@bib19]^ As an antiepileptic, VPA has a long history in the clinic,^[@bib19]^ and we reasoned that side effects would be predictable and manageable.

Lysosomes are involved in the cell death produced by a number of different antitumour drugs, including doxorubicin, camptothecin, cisplatin and etoposide.^[@bib20],\ [@bib21],\ [@bib22]^ The mechanism of lysosome involvement in mediating cell death generally involves its disruption, a phenomenon known as lysosome membrane permeabilization (LMP).^[@bib23],\ [@bib24]^ LMP-associated cell death can be necrotic or apoptotic, and the mechanism of death is thought to be dependent on the degree of LMP, where partial LMP induces apoptosis.^[@bib23],\ [@bib24]^ Once disrupted, various lysosomal enzymes are spilled into the cytoplasm, some of which maintain their activity at physiological pH to mediate cell death. Among them, cathepsins B, D and L have been implicated in LMP-associated cell death.^[@bib25]^ Cathepsin B is one of the most stable proteases at physiological pH and has been shown to mediate LMP-associated cell death in response to doxorubicin, bortezomib, tumour necrosis factor and during mammary involution in mice.^[@bib26],\ [@bib27],\ [@bib28],\ [@bib29]^ Released cathepsin B is active in the cytosol, where it can cleave many caspase targets and anti-apoptotic proteins, including Mcl-1 and XIAP.^[@bib30],\ [@bib31],\ [@bib32]^ However, the role of lysosome-mediated cell death for the activity of antitumour agents in primary CLL cells is largely unstudied. In this study, we describe the role of cathepsin B in mediating VPA- and fludarabine-induced apoptosis in primary CLL cells.

Materials and methods
=====================

Cell culture and treatment conditions
-------------------------------------

The diagnosis of CLL was made by peripheral blood morphology and the presence of monoclonal B cells in the peripheral blood with typical immunophenotype (CD19^+^, CD5^+^ and CD23^+^). Peripheral blood samples were obtained from CLL patients following informed consent, in agreement with the Research Ethics Board at the University of Manitoba. Peripheral blood mononuclear cells were isolated from the buffy coat using a ficoll-paque density gradient as previously described.^[@bib33]^ Freshly isolated CLL cells were cultured in Roswell Park Memorial Institute-1640 culture medium supplemented with 100 U of penicillin, 100 mg of streptomycin and 0.5% bovine serum albumin. Bovine serum albumin supplementation was chosen over fetal bovine serum supplementation for culturing of primary CLL cells, as bovine serum albumin supplementation was associated with lower levels of spontaneous apoptosis ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Three human B-cell leukaemia/lymphoma cell lines, BJAB, I-83 and NALM-6, were cultured in Roswell Park Memorial Institute-1640 culture medium supplemented with 100 U of penicillin, 100 mg of streptomycin and 10% fetal bovine serum.

Reagents used
-------------

Chloroquine, fludarabine, NH~4~Cl, VPA, propidium iodide and trichostatin A were purchased from Sigma-Aldrich (St Louis, MO, USA). Suberoylanilide hydroxamic acid was a gift from Dr Jim Davie (University of Manitoba). Antibodies against Mcl-1, XIAP and caspases-3, -8 and -9 were from Cell Signaling (Danvers, MA, USA). Antibodies against caspase-2 and cathepsin B were from Abcam (Toronto, ON, Canada). Antibodies against glyceraldehyde 3-phosphate dehydrogenase and tubulin were from Sigma (St Louis, MO, USA). Purified cathepsin B was purchased from Abcam. Chemical inhibitors of cathepsins, CA074-Me (Enzo Life Sciences, Farmingdale, NY, USA) and pepstatin A (Sigma), were also obtained commercially.

Cell death assays
-----------------

Nuclear fragmentation was assessed by propidium iodide staining in hypotonic conditions and was performed with minor modifications using the direct DNA staining method.^[@bib34]^ Briefly, cell pellets were resuspended in the propidium iodide staining buffer, supplemented with RNase (100 μg/ml). Cells were stained for 30 min at room temperature in the dark, after which samples were kept on ice and analysed on the flow cytometer within an hour.

Whole-cell lysates and immunoblotting
-------------------------------------

Whole-cell lysates were prepared from cell pellets, which were subjected to a single cycle of freeze thaw at −80 °C, and then resuspended in the radioimmunoprecipitation assay buffer supplemented with the Complete Mini protease inhibitor cocktail (Roche, Laval, QC, Canada), phosphatase inhibitor cocktails (Sigma-Aldrich) and sodium orthovanadate (1 m[M]{.smallcaps}, Sigma-Aldrich). Protein samples were quantified using either the Bradford (Bio-Rad, Mississauga, ON, Canada) or the bicinchoninic acid (Pierce, Rockford, IL, USA) protein quantification assay.

SDS-polyacrylamide gel electrophoresis was performed using standard protocols. Resultant blots were transferred onto nitrocellulose membranes and blocked using 5% milk or 5% bovine serum albumin in tris-buffered saline-Tween-20 (0.1% Tween-20). Blocked membranes were incubated overnight in the primary antibody mix, followed by incubation in the secondary antibody mix (horse radish peroxidase-conjugated anti-mouse/rabbit antibody (Bio-Rad). Enhanced chemiluminescence was performed using commercial reagents (GE Healthcare (Baie d\'Urfe, QC, Canada) or Pierce).

Lysosome visualization
----------------------

Lysosomes were stained using LysoTracker Red DND-99 (Life Technologies, Burlington, ON, Canada). Cells were stained with LysoTracker at 62.5 n[M]{.smallcaps} for 30 min at 37 °C and washed in fresh media before visualization or flow cytometry.

*In vitro* cathepsin B experiments
----------------------------------

Whole-cell lysates were prepared in a lysis buffer containing NP40 supplemented with a protease inhibitor cocktail (Roche). Cell lysate protein was combined with ⩾0.2 U of cathepsin B, which was activated for 15 min at room temperature in the presence of dithiothreitol and phosphate-buffered saline (pH 7.4). The reaction mixtures were incubated at 37 °C, and the reaction was terminated by boiling the samples after the addition of SDS-polyacrylamide gel electrophoresis loading dye and dithiothreitol.

Benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin (zRR-AMC) is a fluorogenic substrate of cathepsin B and was purchased from Enzo Life Sciences. Fresh lysates of treated cells were prepared using the NP40 buffer described above. Lysates were combined with phosphate-buffered saline containing zRR-AMC (100 μ[M]{.smallcaps}) and incubated for 1 h at 37 °C. After an hour of incubation at 37 °C, zRR-AMC cleavage was measured using SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA). To assess the level of background fluorescence, a control without lysate was used.

Phase II clinical trial
-----------------------

CLL patients aged 18 years or older who required therapy, had an ECOG (Eastern Cooperative Oncology Group) performance score of ⩽2 and had been previously treated with a nucleoside analogue were recruited into the trial. Patients were treated with oral VPA at a starting dose of 15 mg/kg per day orally in divided doses, with the goal of reaching a serum level of \>1 m[M]{.smallcaps} through weekly therapeutic drug monitoring and dose escalation. For those with stable or progressive disease following 28 days of therapy, oral fludarabine at a dose of 40 mg/m^2^ per day on days 1--3 of each 28-day cycle was administered in conjunction with VPA. Treatment was continued to a maximum of six cycles. Therapy was discontinued if there was evidence of progressive disease after two cycles of fludarabine and VPA or if the patient experienced unacceptable toxicity attributable to the study drugs, for example, three or more non-haematological toxicity or prolonged grade 4 haematological toxicity NCI (National Cancer Institute criteria).

The primary outcome of interest was best clinical response as defined by the NCIWG (National Cancer Institute Working Group) criteria for CLL 6 months after commencing therapy.^[@bib35]^ Secondary outcomes of interest were the effect of treatment on histone acetylation status and toxicity, both haematological and non-haematological. This trial conformed to good clinical practice guidelines and is registered at NCT00524667.

Statistical analyses
--------------------

Analysis of variance was used to compare multiple columns, and *t*-tests were used for two-column comparisons (the Mann--Whitney). Analysis of variance was followed by post-test column comparison (Tukey\'s test).

Results
=======

A synergistic apoptotic response is observed when HDIs and fludarabine are combined
-----------------------------------------------------------------------------------

VPA has been shown to interact with fludarabine in a synergistic manner against primary CLL cells,^[@bib14],\ [@bib16]^ and this was confirmed when we examined primary CLL cells either co-treated or pretreated for 24 h with VPA and then treated with fludarabine ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}), and similar results were obtained using either Annexin V staining or the sub-G1 method ([Supplementary Figure S1D](#sup1){ref-type="supplementary-material"}). There were no statistically significant differences in response to either fludarabine or the VPA/fludarabine combination in *IgV*~*H*~-mutated or unmutated CLL samples ([Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}). We next examined three B-cell neoplasm-derived cell lines, BJAB, I-83 and NALM-6, which were chosen to represent the spectrum of different B-cell neoplasms, representing immature (NALM-6) to mature (CLL-like I-83) malignancies. Using sublethal dose of VPA (1 m[M]{.smallcaps}), the addition of VPA increased fludarabine cytotoxicity in all three cell lines ([Figure 1a](#fig1){ref-type="fig"}). This increased apoptosis was not observed between fludarabine and valpromide, the amide analogue of VPA that lacks the HDAC inhibition activity,^[@bib36]^ suggesting that HDAC inhibition is important for synergy ([Figure 1a](#fig1){ref-type="fig"}). Fludarabine cytotoxicity was also increased by the addition of three different HDIs at sublethal doses, namely sodium butyrate, trichostatin A and suberoylanilide hydroxamic acid ([Figure 1b](#fig1){ref-type="fig"}). When the status of histone acetylation of histone-3 and histone-4 were examined, the VPA and fludarabine combination induced higher levels of histone acetylation than either agent alone ([Supplementary Figure S1E](#sup1){ref-type="supplementary-material"}). This was associated with an increase in the levels of histone-3 and histone-4 by fludarabine treatment, albeit to a greater extent in BJAB and NALM-6 cells compared with I-83 cells, as well as downregulation of HDAC1 by the VPA/fludarabine combination ([Supplementary Figure S1E](#sup1){ref-type="supplementary-material"}). The combination also induced activation of initiator caspases-2, -8 and -9 and the executioner caspase-3 in cell lines and primary CLL cells ([Figure 1c](#fig1){ref-type="fig"}), suggesting that both the intrinsic and extrinsic apoptotic pathways are activated.

The combination of VPA and fludarabine induces Mcl-1 and XIAP degradation in a lysosome-dependent manner
--------------------------------------------------------------------------------------------------------

In CLL cells, various HDIs have previously been shown to downregulate the anti-apoptotic proteins, Bcl-2, Mcl-1 and XIAP.^[@bib16],\ [@bib17],\ [@bib37]^ In the present study, we found that the levels of XIAP and Mcl-1 were reduced in both primary CLL and cell lines in response to fludarabine, and this reduction was further enhanced when fludarabine was combined with VPA ([Figure 2a](#fig2){ref-type="fig"}). In contrast, the Bcl-2 levels remained unchanged in primary CLL cells, whereas Bcl-2 was not expressed at detectable levels in BJAB or NALM-6 cells. In BJAB cells, the reduction in Mcl-1 and XIAP occurred with 16 h of treatment, and the same reduction was observed with 24-h treatment in primary CLL cells, and these observations were evident before significant apoptosis had occurred ([Supplementary Figures S2A and B](#sup1){ref-type="supplementary-material"}). This suggests that the downregulation of the proteins was contributing to the apoptosis. Interestingly, when the mRNA levels for these proteins were examined, there was no reduction in transcription, and the *XIAP* mRNA levels increased after treatment ([Supplementary Figure S2C and D](#sup1){ref-type="supplementary-material"}), suggesting that Mcl-1 and XIAP downregulation occurs post-transcriptionally.

Protein degradation can occur via a number of different pathways, including autophagy, lysosomal degradation and the ubiquitin--proteasome pathway.^[@bib38],\ [@bib39]^ Under apoptosis, a large number of proteins also become targeted by caspases.^[@bib40]^ In order to investigate which pathways were involved in the degradation of Mcl-1 and XIAP, BJAB cells were pretreated with chloroquine (inhibitor of autophagy and lysosomal pathways), zVAD-fmk (pan-caspase inhibitor) or bortezomib (26S proteasome inhibitor). We determined whether these inhibitors could block protein degradation and caspase activation. Pretreatment with either chloroquine or zVAD-fmk reduced activation of caspases-2 and -8 and partially stabilized Mcl-1 and XIAP in response to fludarabine, in the presence or absence of VPA ([Figure 2b](#fig2){ref-type="fig"}). In contrast, bortezomib increased caspase activation in cells treated with either VPA or fludarabine and did not stabilize XIAP in response to the VPA/fludarabine combination ([Figure 2b](#fig2){ref-type="fig"}). Bortezomib did, however, increase the levels of Mcl-1, as a result of blockage of the ubiquitin--proteasome pathways ([Figure 2b](#fig2){ref-type="fig"}). Taken together, both lysosome and caspases appear to be involved in the degradation of XIAP and Mcl-1 by fludarabine, with or without VPA, and inhibition of the lysosomal protein degradation pathway suppressed caspase activation.

We next investigated the effects of lysosome alkalinization on the level of cell death. Pretreatment with chloroquine or NH~4~Cl reduced cell death in response to the combination of VPA and fludarabine in both BJAB and NALM-6 cells ([Figure 3a](#fig3){ref-type="fig"}). This protection by chloroquine or NH~4~Cl is not associated with inhibition of autophagy, as fludarabine, in the presence or absence of VPA, did not induce the formation of LC3-II (an indicator of autophagy), as determined by immunoblotting and was not associated with increase in the number of acidic vacuoles assessed by acridine orange staining ([Supplementary Figures S3, S4A and B](#sup1){ref-type="supplementary-material"}). Rather, the addition of chloroquine resulted in the increase in steady-state levels of LC3-II because of blockage of its degradation by lysosomes ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). In primary CLL cells, pretreatment with chloroquine or NH~4~Cl reduced VPA/fludarabine- and fludarabine-induced apoptosis, although the magnitude of suppression was much lower, because of the toxicity associated with chloroquine or NH~4~Cl pretreatment ([Figure 3b](#fig3){ref-type="fig"}). In contrast to chloroquine or NH~4~Cl, treatment of BJAB or NALM-6 cells with MG-132 or bortezomib increased VPA and fludarabine cytotoxicity ([Figure 3c](#fig3){ref-type="fig"}). These observations suggest the lysosomes are having a crucial, autophagy-independent role in VPA/fludarabine-induced cell death.

Apoptosis induced by the combination of VPA and fludarabine is cathepsin B-dependent
------------------------------------------------------------------------------------

The lysosome has been implicated in cell death pathways that involve its disruption, known as LMP, leading to the activation of caspases-2 and -8.^[@bib23]^ As the VPA/fludarabine combination activated caspase-2 and lysosome alkalinization protected the cells from the combination, we next determined whether LMP is involved in cell death induced by VPA and fludarabine. In cell lines, staining of acidic compartments using acridine orange showed a loss of acidic compartments in response to fludarabine and VPA ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}). When quantified, the percent of cells with loss of acidic compartments (that is, no detectable acridine orange staining) corresponded with the level of apoptosis ([Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}). We next used LysoTracker, a commercial dye for acidic compartments, to examine primary CLL cells. LysoTracker staining showed a similar loss of acidic compartments in primary CLL cells following treatment, and the loss was visibly obvious by microscopy ([Supplementary Figure S4C](#sup1){ref-type="supplementary-material"}) and by flow cytometry ([Figure 4a](#fig4){ref-type="fig"}). When signals were quantified, LysoTracker signals were significantly reduced in either fludarabine- or VPA/fludarabine-treated cells ([Supplementary Figure S4D](#sup1){ref-type="supplementary-material"}).

Disruption of lysosomes, however, is a phenomenon that is observed in many different modes of cell death where lysosomes may or may not be having a driving role in the induction of cell death.^[@bib41]^ When the disruption of lysosomes do actually drive cell death, such cell death scenarios involve the release of the lysosomal proteases into the cytosol and, among the different proteases, cathepsins B and D have been implicated in such cell deaths.^[@bib23]^ When BJAB or NALM-6 cells were pretreated with CA074-ME, an inhibitor of cathepsin B, there was a robust protection of cells from fludarabine- or VPA/fludarabine-induced apoptosis, whereas much higher concentrations of pepstatin A, an inhibitor of cathepsin D, failed to show any protection ([Figure 4b](#fig4){ref-type="fig"}). Pretreatment of NALM-6 cells with CA-074ME partially stabilized Mcl-1 and XIAP and also reduced the activation of caspases, including caspase-2 ([Figure 4c](#fig4){ref-type="fig"}). Unlike cell lines, treatment of primary CLL cells with CA074-Me (20 μ[M]{.smallcaps}) was toxic, but nonetheless resulted in mild suppression of the cytotoxicity seen with the VPA and fludarabine combination, where the difference approached statistical significance ([Supplementary Figure S4E](#sup1){ref-type="supplementary-material"}).

Although CA074-Me pretreatment partially stabilized Mcl-1 and XIAP, the pretreatment also inhibited the activation of caspases, which may be cleaving Mcl-1 and XIAP on their own. We thus determined whether cathepsin B could directly target Mcl-1 and XIAP, as cathepsin B has been shown to target purified Bcl-2 proteins, including Mcl-1 and XIAP in a cell-free system using purified proteins.^[@bib32]^ We thus simulated LMP by combining whole-cell lysates from BJAB or NALM-6 cells with purified, activated cathepsin B to determine whether cathepsin B could directly degrade Mcl-1 and XIAP *in vitro*. When BJAB or NALM-6 lysates were mixed with purified cathepsin B, there were reductions in Mcl-1 and XIAP levels ([Figure 4d](#fig4){ref-type="fig"}), thus demonstrating that cathepsin B can target Mcl-1 and XIAP. Cathepsin B addition also resulted in the appearance of faster migrating bands with caspase-2 immunoblotting and a reduction in the pro-caspase-2 levels ([Figure 4d](#fig4){ref-type="fig"}). Taken together, treatment of leukaemic cells with fludarabine and VPA induces LMP, and the resulting apoptosis is dependent on the lysosomal protease cathepsin B, which can directly target Mcl-1, XIAP and caspase-2.

VPA upregulates cathepsin B levels and activity
-----------------------------------------------

A microarray study of VPA-treated CLL cells had reported cathepsin B to be upregulated.^[@bib16]^ Treatment of BJAB cells with VPA resulted in increased levels of cathepsin B, which was not observed with valpromide ([Figure 5a](#fig5){ref-type="fig"}). We next asked whether this increase in cathepsin B level was also associated with increase in the cathepsin B activity. Fresh lysates from BJAB or NALM-6 cells that had been treated with either vehicle or 1 m[M]{.smallcaps} VPA was mixed with zRR-AMC, a fluorogenic substrate for cathepsin B whose cleavage product (7-amino-4-methylcoumarin) is fluorescent. Cleavage of zRR-AMC was detectable when combined with either vehicle-treated BJAB or NALM-6 lysates, and this activity was increased in lysates obtained from cells that had been treated for 24 h with 1 m[M]{.smallcaps} VPA ([Figure 5b](#fig5){ref-type="fig"}). Co-treatment of cells with CA074-Me (20 μ[M]{.smallcaps}) reduced the fluorescence to the background level, demonstrating that zRR-AMC cleavage is cathepsin B dependent. In primary CLL cells, similar increase in cathepsin B levels in response to VPA was observable ([Figure 5c](#fig5){ref-type="fig"}), and VPA treatment was sufficient to increase zRR-AMC cleavage with lysates from primary CLL cells ([Figure 5d](#fig5){ref-type="fig"}). Thus, taken together, VPA increases cathepsin B protein levels, and this upregulation is associated with increased cathepsin B activity.

Phase I/II clinical trial data using a VPA and fludarabine combination
----------------------------------------------------------------------

To determine whether VPA and fludarabine give increased clinical efficacy for CLL patients, we conducted a phase I/II clinical trial. Of six patients registered in the trial, three patients were fludarabine resistant and all had received a variety of chemotherapeutic regimens before trial entry ([Table 1](#tbl1){ref-type="table"}). Fludarabine resistance was clinically defined as having failed treatment or relapsed within 6 months of completing prior fludarabine-based therapy as per the international workshop on CLL guidelines.^[@bib42]^ Four patients had Rai stage IV disease and two patients Rai stage III disease. Response with a 28-day cycle of VPA monotherapy was modest, with no response in half of the patients, and VPA was then combined with fludarabine for the remainder of the treatment course. Patients had VPA concentrations in the serum between 0.54--1.1 m[M]{.smallcaps} ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Two patients had progressive disease following therapy, three patients had stable disease with \>50% decrease in lymphocyte count following five cycles of therapy and one patient had a partial remission at the completion of six cycles of therapy ([Figure 6a](#fig6){ref-type="fig"}, [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Two patients completed all planned cycles of therapy. Two patients developed significant anaemia (NCI CTC grade 4) and one patient developed significant fatigue (NCIC CTC grade 3) during the fifth cycle of therapy necessitating early treatment discontinuation. Nevertheless, out of the six patients, five showed a decrease in lymphocyte count and lymph node sizes ([Figures 6a and b](#fig6){ref-type="fig"}).

To evaluate whether VPA is targeting histone acetylation and cathepsin B expression *in vivo*, peripheral blood samples were obtained during the first 30 days of the treatment course on VPA monotherapy and mononuclear cells were isolated for analysis by immunoblotting. Levels of both histone-3 acetyl initially increased and then fluctuated during the course of treatment ([Figure 6c](#fig6){ref-type="fig"}, [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). More importantly, cathepsin B expression was increased on average 2.3-fold in four patients\' CLL cells over a 30-day time course following VPA treatment ([Figure 6d](#fig6){ref-type="fig"}). The increase in cathepsin B levels were similar to those seen in VPA-treated primary CLL cells *in vitro* and corresponded to the subsequent decrease in lymphocyte count when fludarabine was added ([Figure 6a](#fig6){ref-type="fig"}).

Discussion
==========

Although it has recently become apparent that the lysosome can contribute to cell death, this activity has been largely unstudied in CLL. The lysosome is the ultimate target for the TOSO:IgM complex in CLL cells, thereby contributing to the regulation of the BCR signalling pathway.^[@bib43]^ In the context of rituximab, a type I anti-CD20 monoclonal antibody, the lysosome is the ultimate destination for FcγRIIB-promoted internalization of CD20:anti-CD20 complexes leading to reduced expression of CD20 on the cell surface, thereby contributing to rituximab resistance.^[@bib44]^ On the other hand, GA101, a type II anti-CD20 monoclonal antibody, induces lysosome-dependent cell death, which was increased with CD40 ligation.^[@bib45]^ Thus, lysosome-mediated cell death may be a novel mechanism to kill CLL cells.

In this study, we describe the involvement of the lysosome in fludarabine- and VPA/fludarabine-induced death of CLL cells. Although the GA101-induced cell death was described as being non-apoptotic,^[@bib45]^ VPA with fludarabine treatment induced DNA fragmentation, phosphatidylserine externalization, nuclear condensation (data not shown) and the activation of multiple caspases, thus demonstrating that the cell death is apoptotic in nature. The difference between the treatments with GA101 versus VPA and fludarabine could be due to the extent of LMP. It is known that LMP can lead to both apoptosis and necrosis, depending on the extent of LMP; necrosis appears to be the dominant pathway of death in the setting of massive LMP, whereas partial LMP drives apoptotic cell death.^[@bib23]^ GA101-induced LMP was rapid and obvious after hours of treatment,^[@bib45]^ whereas fludarabine-induced LMP was much slower in comparison. By simulating LMP, we show that activated cathepsin B can target anti-apoptotic proteins, Mcl-1 and XIAP, as well as caspase-2. Considering the importance of the anti-apoptotic proteins in CLL cell survival, especially in the tumour microenvironment,^[@bib46]^ targeting their degradation through cathepsin B could be a novel strategy to reduce drug resistance in the CLL microenvironment. In line with this hypothesis, we observed shrinkage of the lymph nodes in four of the six patients treated with the VPA/fludarabine combination, and we believe cathepsin B activation and release contributed to this clinical observation. The role of cathepsin B in the tumour microenvironment will be a focus of future investigations.

Some HDIs have also been described to cause LMP itself. Sulforaphane monotherapy has been observed to induce LMP,^[@bib47]^ and the release of cathepsin B was found to contribute to the toxicity of doxorubicin when combined with HDIs.^[@bib48]^ In this study, VPA upregulated cathepsin B levels in cell lines, primary CLL cells *in vitro* and in the leukaemic cells of CLL patients treated in the clinic, resulting in increased protease activity in cell lysates. As cathepsin B itself has been found to be important for the disruption of lysosomes,^[@bib49]^ the increase in cathepsin B activity is likely to be sensitizing the lysosomes to LMP, as well as the subsequent cathepsin B-dependent protein degradation. In early studies that examined the biochemical activity of lysosomal enzymes in CLL, such as acid phosphatases and β-glucuronidases, peripheral blood CLL cells showed lower activity compared with normal lymphocytes,^[@bib50]^ whereas another study showed CLL samples to have lower lysosomal acid phosphatase activity compared with other lymphomas.^[@bib51]^ Although VPA had little activity when used alone in CLL patients, it increased cathepsin B levels in the cells of all four patients examined. In addition, there was a synergistic response between VPA and fludarabine in primary CLL cells *in vitro*, and as VPA produced a similar effect on the cathepsin B levels in CLL cells in treated patients, it is likely that VPA contributed to the clinical response. Thus, upregulation of cathepsin B levels would be a sensible and rational adjunct strategy for lysosome-targeted therapy.
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![Cytotoxicity of fludarabine is enhanced by HDIs. (**a**) Three human leukaemic cell lines, BJAB, NALM-6 and I-83, were treated for 1 day using combinations of fludarabine (5 μ[M]{.smallcaps}) with valproic acid (VPA, 1 m[M]{.smallcaps}) or valpromide (VPA analogue that does not target HDACs, 1 m[M]{.smallcaps}). DNA fragmentation was quantified by flow cytometry, examining for hypodiploid DNA content. (**b**) Fludarabine (5 μ[M]{.smallcaps}) was combined with three other HDIs, sodium butyrate (1 m[M]{.smallcaps}), trichostatin A (5 n[M]{.smallcaps}) or suberoylanilide hydroxamic acid (5 μ[M]{.smallcaps}) in BJAB or NALM-6 cells for 1-day treatment. (**c**) Immunoblots using whole-cell lysates to examine caspase activation. Cell lines were treated for 1 day and primary CLL cells were treated for 2 days using combinations of fludarabine (5 μ[M]{.smallcaps} for cell lines, 10 μ[M]{.smallcaps} for primary CLL cells) and VPA (1 m[M]{.smallcaps}). Bar=mean, error bar=one s.e.m. Primary CLL data shown are representative data, and all experiments were repeated at least three independent times. \*\*\* represents significant differences in vehicles versus VPA treated cells in the presence of fludarabine.](bcj201350f1){#fig1}

![The role of different protein degradation pathways in Mcl-1 and XIAP degradation. (**a**) Cell lines were treated for 1 day and primary CLL cells were treated for 2 days using combinations of fludarabine (5 μ[M]{.smallcaps} for cell lines, 10 μ[M]{.smallcaps} for primary CLL cells) and VPA (1 m[M]{.smallcaps}). Whole-cell lysates were examined for the levels of Bcl-2, Mcl-1 and XIAP in response to the indicated treatment combinations. Primary CLL data shown are representative data. (**b**) BJAB cells were pretreated with vehicles, chloroquine (an inhibitor of the lysosomal protein degradation), zVAD.fmk (a pan-caspase inhibitor) or bortezomib (a 26S proteasome inhibitor) for 1 h, and then treated with the indicated combinations of fludarabine and VPA for 16 h. Whole-cell lysates were examined by immunoblotting. The data shown for different treatments are obtained from a single representative experiment from the same membrane. All experiments were repeated three independent times.](bcj201350f2){#fig2}

![Inhibition of the endolysosomal pathway protects cells from VPA-fludarabine cytotoxicity. (**a**, **b**) BJAB, NALM-6 or primary CLL cells were pretreated for 1 h with two different inhibitors of the lysosomal protein degradation pathway, chloroquine (100 μ[M]{.smallcaps}) or NH~4~Cl (50 m[M]{.smallcaps}), and then treated for 1 (cell lines) or 2 (primary CLL cells) days using the indicated combinations of fludarabine (5 μ[M]{.smallcaps} for cell lines, 10 μ[M]{.smallcaps} for primary CLL cells) and VPA (1 m[M]{.smallcaps}). Data are gathered from 11 CLL patient samples. (**c**) BJAB or NALM-6 cells were pretreated with two inhibitors of the 26S proteasomal protein degradation pathway, MG-132 (1 μ[M]{.smallcaps}) or bortezomib (1 n[M]{.smallcaps}), and then treated for 1 day using the indicated combinations of fludarabine (5 μ[M]{.smallcaps}) and VPA (1 m[M]{.smallcaps}). Bar=mean, error bar=one s.e.m. All experiments in cell lines were repeated at least three independent times. \* represents significant differences between vehicle and chloroquine treated cells in primary CLL cells. \*\* represents significant differences between vehicle and chloroquine or NH~4~CL in cell lines. \*\*\* represents significant differences between vehicle and NH~4~CL treatments in primary CLL cells.](bcj201350f3){#fig3}

![The role of cathepsin B in VPA-fludarabine cytotoxicity. (**a**) Flow cytometric analysis of a representative CLL patient sample using LysoTracker staining of the lysosomes. Primary CLL cells were treated for 2 days using the indicated combinations of fludarabine (10 μ[M]{.smallcaps}) and VPA (1 m[M]{.smallcaps}). Loss of lysosomal integrity is indicated by decrease in LysoTracker staining intensity. (**b**) BJAB or NALM-6 cells were pretreated for 1 h using CA074-Me, a permeable cathepsin B inhibitor or pepstatin A, a cathepsin D inhibitor, and then treated for 1 day using the indicated combinations of fludarabine (5 μ[M]{.smallcaps}) and VPA (1 m[M]{.smallcaps}). (**c**) Whole-cell lysates from **b** examined via immunoblotting. (**d**) BJAB or NALM-6 cell lysates (10 μg each) was combined with activated, purified cathepsin B and incubated for the indicated durations. Reactions were stopped by adding SDS-polyacrylamide gel electrophoresis loading dye supplemented with dithiothreitol (50 m[M]{.smallcaps}) and boiling the samples for 5 min before analysis via SDS-polyacrylamide gel electrophoresis and immunoblotting. Bar=mean, error bar=one s.e.m. Primary CLL data shown are representative data, and all experiments in cell lines were repeated at least three independent times. \*\* represents significant differences between vehicle and pepstatin A treatments in cell lines.](bcj201350f4){#fig4}

![The effect of VPA on cathepsin B level and activity. (**a**) BJAB cells were treated using either VPA at indicated doses or valpromide (1 m[M]{.smallcaps}, VPA analogue that does not inhibit HDACs) for 1 day, and whole-cell lysates were examined. (**b**) BJAB or NALM-6 cells were treated for 1 day using the indicated combinations of VPA (1 m[M]{.smallcaps}) and CA074-Me (20 μ[M]{.smallcaps}, a cathepsin B inhibitor), and then 40 μg of whole-cell lysates were combined with zRR-AMC, a fluorogenic substrate for cathepsin B in phosphate-buffered saline (pH 7.4). (**c**) Two primary CLL samples were treated using the indicated doses of VPA for 2 days, and whole-cell lysates were examined via immunoblotting. (**d**) Primary CLL cells were treated for 2 days using VPA (1 m[M]{.smallcaps}). Cells were collected and 15 μg of whole-cell lysates were combined with zRR-AMC as in **b**. The data are obtained from experiments with six different CLL samples. Bar=mean, error bar=one s.e.m. Primary CLL data shown are representative data, and all experiments were repeated at least three independent times. \* represents significant differences between untreated and VPA treated primary CLL cells. \*\* represents significant differences between untreated and VPA treated cell lines in the presence of vehicle.](bcj201350f5){#fig5}

![Clinical and translational data. (**a**) Absolute lymphocyte count values of the six patients enrolled in the clinical trial. (**b**) Waterfall plot of best decrease in lymph node sizes. (**c**) Whole-cell lysates obtained from four patients while undergoing VPA monotherapy at indicated times. (**d**) Densitometry was performed on cathepsin B cells in CLL cells and normalized to glyceraldehyde 3-phosphate dehydrogenase.](bcj201350f6){#fig6}

###### Patient characteristics before study

  *Patient*   *Age at study*    *Sex*   *Rai stage*        *Previous treatments*         *IgV*~*H*~   *ZAP70*    *FLU sensitivity*[a](#t1-fn2){ref-type="fn"}
  ----------- ---------------- ------- ------------- ---------------------------------- ------------ ---------- ----------------------------------------------
  1           78                  M         IV               CLB→FLU+Dex→FRD→CR              U           NA                       Resistant
  2           72                  M         IV                     FLU→FC                    U        Positive                    Sensitive
  3           72                  M         IV                  CLB+Pred→FC                  U           NA                       Resistant
  4           70                  M         IV                     FLU→FC                    M        Negative                    Sensitive
  5           79                  F         III              CLB→FR→FLU→FCR→FR               NA       Negative                    Resistant
  6           62                  M         IV        CLB→Flu→CLB→RCVP→RCHOP→CLB→/RCVP       NA          NA                       Sensitive

Abbreviations: CLB, chlorambucil; CR, cyclophosphamide/rituximab; Dex, dexamethasone; FC, fludarabine/cyclophosphamide; FCR, fludarabine/cyclophosphamide/rituximab; FLU, fludarabine; FRD, fludarabine/rituximab/dexamethasone; M, mutated; NA=not available; Pred, prednisolone; U, unmutated.

FLU resistant=no response with FLU or relapse\<6 M after the completion of treatment with FLU.
